Symbols

KMDA

Kamada·NASDAQ

--(--)

KMDA fundamentals

KMDA Q4 2025 Earnings

Kamada (KMDA) released its earnings on Mar 11, 2026: revenue was 44.68M (YoY +14.54%), missed estimates; EPS was 0.0677 (YoY -7.39%), missed estimates.

Revenue / YoY

44.68M

+14.54%

EPS / YoY

0.0677

-7.39%

Report date

Mar 11, 2026

KMDA Earnings Call Summary for Q4,2025

Record 2025 Performance: $180.5M revenue (+12%), $42M EBITDA (+23%), and $75.5M cash, with $0.25/share dividend.
2026 Growth Targets: $200-205M revenue (+13%) and $50-53M EBITDA (+23%) via organic expansion.
Strategic Wins: KEDRAB ($54M), VARIZIG WHO tender, and 2 new biosimilars launching mid-2026.
Plasma Center Timeline: San Antonio FDA approval by H1 2026, full specialty plasma impact from 2027.
M&A Confidence: Active pipeline with potential 2026 deals, despite dividend payout.

Earnings

EPS

Revenue

Revenue & Expenses

KMDA has released its 2025 Q4 earnings report, with revenue of 44.68M, reflecting a YoY change of 14.54%, and net profit of 3.56M, showing a YoY change of -6.46%. The Sankey diagram below clearly presents KMDA's revenue sources and cost distribution.

Key Indicators

Kamada (KMDA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Kamada (KMDA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Kamada (KMDA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Kamada (KMDA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown